Economical data and advanced prostate carcinoma: Do we need new guidelines for decision making?

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1185-1188

  Rohde, Volker ^a   Wellmann, Axel ^c   Fogt, Franz ^d   Weidner, Wolfgang ^a   Katalinic, Alexander ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d 1010 Vagelos Research Labs   (United States)

Author keywords

Advanced prostate carcinoma; Cost analysis; Hormone deprivation; Medical decision making; Quality of life

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ARTICLE; BLOOD; COST; DECISION MAKING; DISEASE COURSE; ECONOMICS; HEALTH CARE COST; HUMAN; INCIDENCE; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRACTICE GUIDELINE; PROSTATE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COSTS AND COST ANALYSIS; DECISION MAKING; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HEALTH CARE COSTS; HUMANS; INCIDENCE; MALE; ORCHIECTOMY; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036834210     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1185     Document Type: Article

References (17)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (ABKD). Krebs in Deutschland. 2nd edition. Saarbrücken, 1999.
2. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL and Wilt TJ: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132: 566-577, 2000. (Pubitemid 30171897)
3. Hillner BE and Roberts JD: Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst 92: 1704-1706, 2000.
4. Holtgrewe HL, Bay-Nielsen H and Bouffioux C: The economics of prostate cancer. In: First International Consultation on Prostate Cancer. Murphy G, Griffiths K, Denis L, et al (eds). Scientific Communication International Ltd., London, pp399, 1997.
5. Mariani AJ, Glover M and Arita S: Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 165: 104-107, 2001.
6. Hölzel D, Klammert A and Schmidt MK: Krebs: Häufigkeiten, Befunde und Behandlungsergebnisse. Z Zuckschwert, 1996.
7. Wirth M and Froehner M: A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 36 (Suppl 2): 14-19, 1999. (Pubitemid 29478970)
8. Iversen P: Quality of life issues relating to endocrine treatment options. Eur Urol 36 (Suppl 2): 20-26, 1999.
9. Nygard R, Norum J and Due J: Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 21: 781-788, 2001. (Pubitemid 32267611)
10. Bonzani RA, Stricker HJ, Peabody J and Menon M: Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 160: 2446-2449, 1998.
11. Herr HW and O'Sullivan M: Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743-1746, 2000. (Pubitemid 30366726)
12. Parmar H, Edwards L, Phillips RH, Allen L and Lightman SL: Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 59: 248-254, 1987. (Pubitemid 17037977)
13. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ and Kennealey GT: Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1: 323-329, 1992.
14. Herr HW: Quality of life in prostate cancer patients. CA Cancer J Clin 47: 207-217, 1997.
15. Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI and Kennealey GT: Patients' choice of treatment in stage D prostate cancer. Urology 33 (Suppl): 57-62, 1989. (Pubitemid 19123268)
16. Chadwick DJ, Gillatt DA and Gingell JC: Medical or surgical orchidectomy: the patients' choice. BMJ 302: 572, 1991.
17. Chon JK, Jacobs SC and Naslund MJ: The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol 164: 735-737, 2000. (Pubitemid 30637613)